Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians-Universität München, Butenandtstr. 5, D-81377 Munich, Germany.
Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians-Universität München, Butenandtstr. 5, D-81377 Munich, Germany.
Int J Pharm. 2019 Mar 25;559:192-200. doi: 10.1016/j.ijpharm.2019.01.015. Epub 2019 Jan 18.
Protein aggregates have been discussed for a long time as a potential risk factor for immunogenicity in patients. Meanwhile, many research groups have investigated the immunogenicity of differently produced aggregates using in vitro or in vivo models. Despite all knowledge gained in these studies still little is known about the mechanisms of immunogenicity and the kind of protein aggregates bearing the greatest risk for immunogenicity. The choice of a suitable test model regarding the predictability of immunogenicity of protein aggregates in humans plays a major role and influences results and conclusions substantially. In this review we will provide an overview of the test models recently used for the evaluation of immunogenicity of protein aggregates; we will discuss advantages and drawbacks regarding their usability and predictive power for immunogenicity in humans.
蛋白质聚集体作为患者免疫原性的一个潜在风险因素已经被讨论了很长时间。同时,许多研究小组已经使用体外或体内模型研究了不同产生的聚集体的免疫原性。尽管在这些研究中获得了所有知识,但对于免疫原性的机制以及对免疫原性风险最大的蛋白质聚集体的种类仍然知之甚少。选择合适的测试模型对于预测蛋白质聚集体在人类中的免疫原性起着重要作用,并会显著影响结果和结论。在这篇综述中,我们将概述最近用于评估蛋白质聚集体免疫原性的测试模型;我们将讨论它们在人类免疫原性中的可用性和预测能力方面的优缺点。